ClinicalTrials.gg
CompletedNCT00141102CONDORUpdated Mar 3, 2021Results posted

Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis

A Phase 4 interventional study of Celecoxib and Diclofenac + Omeprazole in Osteoarthritis and Arthritis, Rheumatoid, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 195 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4,484
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing celecoxib in Osteoarthritis — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis.

Enrollment
3rd of 14
4,484 · median 150
Started
2005
the only one that year
Phase 4
10 of 14
1 open now
Registered
3rd of 14
by date
Lead sponsor
4 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing celecoxib in Osteoarthritis, this one is the 3rd largest by enrollment, is the only one that started in 2005, is one of 10 in phase 4, and was the 3rd registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, or all of them as a file.
02

Study summary

To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis and/or rheumatoid arthritis.

03

Conditions studied

  • Osteoarthritis
  • Arthritis, Rheumatoid

Keywords

  • GI events in high risk GI arthritis patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a clinical diagnosis of OA or RA and who are expected to require regular anti-inflammatory therapy for arthritis symptom management
  • Subjects must be aged 60 years or older with or without a history of gastroduodenal (GD) ulceration; or be of any age 18 years or older and have had documented evidence of GD ulceration 90 days or more prior to the screening visit

Exclusion criteria

Exclusion Criteria:

  • Active GD ulceration or GD ulceration within 90 days of the screening visit.
  • Concomitant use of low dose aspirin
  • Previous MI, stroke or significant vascular disease.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
4,484 participants (actual)

Study arms

  • Experimental
    A

    Drug: Celecoxib

  • Active comparator
    B

    Drug: Diclofenac + Omeprazole

Interventions

  • Participants are assigned to one of two groups in parallel for the duration of the study

  • DrugDiclofenac + Omeprazole

    Drug pages: Diclofenac · Omeprazole

    Participants are assigned to one of two groups in parallel for the duration of the study

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)

    CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments.

    Time frame: 6 month treatment duration

Secondary outcomes

  1. Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs)

    CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU.

    Time frame: 6 month treatment duration

  2. Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET)

    Subjects rated response to question: "Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today?" using a 1 to 5 grading scale where 1=very good and 5=very poor.

    Time frame: Month 6/Early Termination (ET)

  3. Number of Subjects With SUs

    Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU.

    Time frame: 6 month treatment duration

  4. Number of Subjects With CSULGIEs by History of GD Ulceration

    CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments.

    Time frame: 6 month treatment duration

  5. Number of Subjects With Moderate to Severe Abdominal Symptoms

    Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to "Gastrointestinal Signs and Symptoms".

    Time frame: 6 month treatment duration

  6. Number of Subjects Withdrawn Due to GI Adverse Events (AEs)

    GI AEs were defined using MedDRA SOC "Gastrointestinal Disorders" but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions.

    Time frame: 6 month treatment duration

  7. Change From Baseline in Hemoglobin at Month 6/ET

    Time frame: Month 6/ET

  8. Change From Baseline in Hematocrit at Month 6/ET

    Time frame: Month 6/ET

  9. Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin

    A clinically significant decrease from baseline was defined as a fall in hematocrit \> = 10 percentage points and/or hemoglobin \> = 2 g/dL.

    Time frame: 6 month treatment duration

  10. Number of Subjects With Hepatic AEs in Gamma Glutamyl-Transferase (GGT), Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) of 3 Times the Upper Limit of Normal (ULN)

    GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males.

    Time frame: 6 month treatment duration

  11. Change From Baseline in Hepatic Measures of GGT, AST or ALT to Month 6/ET

    Time frame: Month 6/ET

  12. Change From Baseline in Iron Binding Capacity to Month 6/ET

    Time frame: Month 6/ET

  13. Change From Baseline in Ferretin to Month 6/ET

    Time frame: Month 6/ET

  14. Change From Baseline in C-Reactive Protein to Month 6/ET

    Time frame: Month 6/ET

Other outcomes

  1. Number of Subjects Alive at the Post Trial Interview

    Interview occurred via telephone to obtain follow-up mortality and hospitalization information.

    Time frame: 6 months following last dose

  2. Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview

    Interview occurred via telephone to obtain follow-up mortality and hospitalization information.

    Time frame: 6 months following last dose

07

Results

Posted Jun 11, 2010

Participant flow

Participant flow — Overall Study
MilestoneCelecoxibOral Diclofenac Plus Omeprazole
Started22382246
Received treatment22232237
Completed17301621
Not completed508625
Withdrew: Adverse event233305
Withdrew: Laboratory abnormality933
Withdrew: Lack of efficacy2126
Withdrew: Lost to follow-up2932
Withdrew: Other8776
Withdrew: Withdrawal by subject112142
Withdrew: Randomized but did not receive treatment159
Withdrew: Death22

Outcome measures

PrimaryNumber of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)

CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments.

Time frame:
6 month treatment duration
Reported as:
Number · participants
Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)
participantsCelecoxibOral Diclofenac Plus Omeprazole
Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)2081
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · Life Table Extension · p = <0.0001 · Odds ratio (or): 4.32Stratified by history of GD ulceration and by region.
SecondaryNumber of Subjects With CSULGIES or Symptomatic Ulcers (SUs)

CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU.

Time frame:
6 month treatment duration
Reported as:
Number · participants
Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs)
participantsCelecoxibOral Diclofenac Plus Omeprazole
Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs)2592
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · Life Table Extension · p = <0.0001 · Odds ratio (or): 3.93Stratified by history of GD ulceration and by region.
SecondaryChange From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET)

Subjects rated response to question: "Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today?" using a 1 to 5 grading scale where 1=very good and 5=very poor.

Time frame:
Month 6/Early Termination (ET)
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET)
scores on a scaleCelecoxibOral Diclofenac Plus Omeprazole
Change From Baseline in Patient's Global Arthritis Assessment at Month 6/Early Termination (ET)0.754 ± 0.0200.773 ± 0.019
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · ANCOVA · p = 0.4146 · Least squares (ls) mean difference: -0.019 · 95% CI -0.06 to 0.03Fixed effects of region and history of GD ulceration with Baseline covariate.
SecondaryNumber of Subjects With SUs

Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU.

Time frame:
6 month treatment duration
Reported as:
Number · participants
Number of Subjects With SUs
participantsCelecoxibOral Diclofenac Plus Omeprazole
Number of Subjects With SUs511
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · Life Table Extension · p = 0.1132 · Odds ratio (or): 2.29Stratified by history of GD ulceration and by region.
SecondaryNumber of Subjects With CSULGIEs by History of GD Ulceration

CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments.

Time frame:
6 month treatment duration
Reported as:
Number · participants
Number of Subjects With CSULGIEs by History of GD Ulceration
participantsCelecoxibOral Diclofenac Plus Omeprazole
History of GD Ulceration (n=395, 400)713
No History of GD Ulceration (n=1843, 1846)1368
SecondaryNumber of Subjects With Moderate to Severe Abdominal Symptoms

Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to "Gastrointestinal Signs and Symptoms".

Time frame:
6 month treatment duration
Reported as:
Number · participants
Number of Subjects With Moderate to Severe Abdominal Symptoms
participantsCelecoxibOral Diclofenac Plus Omeprazole
Number of Subjects With Moderate to Severe Abdominal Symptoms132162
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · Life Table Extension · p = 0.0495 · Odds ratio (or): 1.26Stratified by history of GD ulceration and by region.
SecondaryNumber of Subjects Withdrawn Due to GI Adverse Events (AEs)

GI AEs were defined using MedDRA SOC "Gastrointestinal Disorders" but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions.

Time frame:
6 month treatment duration
Reported as:
Number · participants
Number of Subjects Withdrawn Due to GI Adverse Events (AEs)
participantsCelecoxibOral Diclofenac Plus Omeprazole
Number of Subjects Withdrawn Due to GI Adverse Events (AEs)114167
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · Life Table Extension · p = 0.0006 · Odds ratio (or): 1.52Stratified by history of GD ulceration and by region.
SecondaryChange From Baseline in Hemoglobin at Month 6/ET
Time frame:
Month 6/ET
Reported as:
Least squares mean · grams (g)/deciliter (dL)
Change From Baseline in Hemoglobin at Month 6/ET
grams (g)/deciliter (dL)CelecoxibOral Diclofenac Plus Omeprazole
Change From Baseline in Hemoglobin at Month 6/ET-0.017 ± 0.019-0.423 ± 0.019
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · ANCOVA · p = <0.0001 · Ls mean difference: 0.406 · 95% CI 0.36 to 0.45Fixed effects of region and history of GD ulceration with Baseline covariate.
SecondaryChange From Baseline in Hematocrit at Month 6/ET
Time frame:
Month 6/ET
Reported as:
Least squares mean · percent
Change From Baseline in Hematocrit at Month 6/ET
percentCelecoxibOral Diclofenac Plus Omeprazole
Change From Baseline in Hematocrit at Month 6/ET-0.306 ± 0.059-1.425 ± 0.059
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · ANCOVA · p = <0.0001 · Ls mean difference: 1.118 · 95% CI 0.98 to 1.25Fixed effects of region and history of GD ulceration with Baseline covariate.
SecondaryNumber of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin

A clinically significant decrease from baseline was defined as a fall in hematocrit \> = 10 percentage points and/or hemoglobin \> = 2 g/dL.

Time frame:
6 month treatment duration
Reported as:
Number · participants
Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin
participantsCelecoxibOral Diclofenac Plus Omeprazole
Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin45123
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · Cochran-Mantel-Haenszel · p = <0.0001 · Relative risk: 2.748 · 95% CI 1.96 to 3.84Stratified by history of GD ulceration and by region.
SecondaryNumber of Subjects With Hepatic AEs in Gamma Glutamyl-Transferase (GGT), Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) of 3 Times the Upper Limit of Normal (ULN)

GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males.

Time frame:
6 month treatment duration
Reported as:
Number · participants
Number of Subjects With Hepatic AEs in Gamma Glutamyl-Transferase (GGT), Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) of 3 Times the Upper Limit of Normal (ULN)
participantsCelecoxibOral Diclofenac Plus Omeprazole
GGT2686
AST812
ALT1327
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · Fisher Exact · p = <0.0001 · Relative risk: 3.329 · 95% CI 2.156 to 5.141
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · Fisher Exact · p = 0.3809 · Relative risk: 1.509 · 95% CI 0.618 to 3.684
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · Fisher Exact · p = 0.0264 · Relative risk: 2.089 · 95% CI 1.081 to 4.038
SecondaryChange From Baseline in Hepatic Measures of GGT, AST or ALT to Month 6/ET
Time frame:
Month 6/ET
Reported as:
Least squares mean · IU/L
Change From Baseline in Hepatic Measures of GGT, AST or ALT to Month 6/ET
IU/LCelecoxibOral Diclofenac Plus Omeprazole
GGT-2.689 ± 0.5917.455 ± 0.592
AST-0.901 ± 0.2391.490 ± 0.239
ALT-1.151 ± 0.3645.213 ± 0.364
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · ANCOVA · p = <0.0001 · Ls mean difference: -10.144 · 95% CI -11.51 to -8.78
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · ANCOVA · p = <0.0001 · Ls mean difference: -2.391 · 95% CI -2.94 to -1.84
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · ANCOVA · p = <0.0001 · Ls mean difference: -6.364 · 95% CI -7.20 to -5.52
SecondaryChange From Baseline in Iron Binding Capacity to Month 6/ET
Time frame:
Month 6/ET
Reported as:
Least squares mean · microgram (ug)/dL
Change From Baseline in Iron Binding Capacity to Month 6/ET
microgram (ug)/dLCelecoxibOral Diclofenac Plus Omeprazole
Change From Baseline in Iron Binding Capacity to Month 6/ET2.517 ± 1.1581.952 ± 1.161
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · ANCOVA · p = 0.6795 · Ls mean difference: 0.565 · 95% CI -2.11 to 3.24Fixed effects of region and history of GD ulceration with Baseline covariate.
SecondaryChange From Baseline in Ferretin to Month 6/ET
Time frame:
Month 6/ET
Reported as:
Least squares mean · ug/dL
Change From Baseline in Ferretin to Month 6/ET
ug/dLCelecoxibOral Diclofenac Plus Omeprazole
Change From Baseline in Ferretin to Month 6/ET-3.396 ± 2.224-1.990 ± 2.228
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · ANCOVA · p = 0.5920 · Ls mean difference: -1.406 · 95% CI -6.55 to 3.74Fixed effects of region and history of GD ulceration with Baseline covariate.
SecondaryChange From Baseline in C-Reactive Protein to Month 6/ET
Time frame:
Month 6/ET
Reported as:
Least squares mean · mg/dL
Change From Baseline in C-Reactive Protein to Month 6/ET
mg/dLCelecoxibOral Diclofenac Plus Omeprazole
Change From Baseline in C-Reactive Protein to Month 6/ET0.058 ± 0.0320.073 ± 0.032
Statistical analysis
  • Celecoxib vs Oral Diclofenac Plus Omeprazole · ANCOVA · p = 0.6819 · Ls mean difference: -0.015 · 95% CI -0.09 to 0.06Fixed effects of region and history of GD ulceration with Baseline covariate.
Other pre-specifiedNumber of Subjects Alive at the Post Trial Interview

Interview occurred via telephone to obtain follow-up mortality and hospitalization information.

Time frame:
6 months following last dose
Reported as:
Number · participants
Number of Subjects Alive at the Post Trial Interview
participantsCelecoxibOral Diclofenac Plus Omeprazole
Number of Subjects Alive at the Post Trial Interview20182023
Other pre-specifiedNumber of Subjects Hospitalized in Last 6 Months at the Post Trial Interview

Interview occurred via telephone to obtain follow-up mortality and hospitalization information.

Time frame:
6 months following last dose
Reported as:
Number · participants
Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview
participantsCelecoxibOral Diclofenac Plus Omeprazole
Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview8279

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib—61/2,223 (2.7%)530/2,223 (23.8%)
Oral Diclofenac Plus Omeprazole—61/2,237 (2.7%)669/2,237 (29.9%)
Most frequent serious events
Showing 10 of 136
Most frequent serious events
EventCelecoxibOral Diclofenac Plus Omeprazole
OsteoarthritisMusculoskeletal and connective tissue disorders4/22234/2237
PyrexiaGeneral disorders3/22231/2237
NauseaGastrointestinal disorders1/22233/2237
Acute myocardial infarctionCardiac disorders2/22232/2237
Duodenal ulcerGastrointestinal disorders2/22230/2237
Gastric ulcerGastrointestinal disorders2/22232/2237
CholelithiasisHepatobiliary disorders2/22232/2237
CellulitisInfections and infestations2/22231/2237
Transient ischaemic attackNervous system disorders2/22230/2237
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/22230/2237
Most frequent other events
Most frequent other events
EventCelecoxibOral Diclofenac Plus Omeprazole
DiarrhoeaGastrointestinal disorders79/2223168/2237
DyspepsiaGastrointestinal disorders137/2223111/2237
Abdominal pain upperGastrointestinal disorders96/2223133/2237
HypertensionVascular disorders76/222384/2237
Haemoglobin decreasedInvestigations27/222372/2237
Oedema peripheralGeneral disorders46/222367/2237
HeadacheNervous system disorders66/222348/2237
NauseaGastrointestinal disorders33/222366/2237
NasopharyngitisInfections and infestations55/222346/2237
GastritisGastrointestinal disorders32/222344/2237

Baseline characteristics

Age, Customized
Age, Customized(participants)CelecoxibOral Diclofenac Plus OmeprazoleTotal
< 55 years176164340
55 to 59 years122113235
60 to 64 years7217421463
65 to 69 years6236181241
70 to 74 years361390751
> = 75 years235219454
Sex: Female, Male
Sex: Female, Male(Participants)CelecoxibOral Diclofenac Plus OmeprazoleTotal
Female184818223670
Male390424814
08

Study locations

195 sites
  • Pfizer Investigational Site
    Genk, 3600, Belgium
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Hasselt, 3500, Belgium
  • Pfizer Investigational Site
    Liège, 4000, Belgium
  • Pfizer Investigational Site
    Goiânia, GO 74043-110, Brazil
  • Pfizer Investigational Site
    Goiânia, GO 74110-120, Brazil
  • Pfizer Investigational Site
    Curitiba, PR 80060-240, Brazil
  • Pfizer Investigational Site
    Curitiba, PR 80060-900, Brazil
  • Pfizer Investigational Site
    Rio de Janeiro, RJ 22271-100, Brazil
  • Pfizer Investigational Site
    Porto Alegre, RS 90035-903, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 04230-000, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 05403-010, Brazil
  • Pfizer Investigational Site
    São Paulo, SP 05437-010, Brazil
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3A 1M3, Canada
  • Pfizer Investigational Site
    St. John's, Newfoundland and Labrador A1B 3E1, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8N 1Y2, Canada
  • Pfizer Investigational Site
    Newmarket, Ontario L3Y 3R7, Canada
  • Pfizer Investigational Site
    Windsor, Ontario N8X 5A6, Canada
  • Pfizer Investigational Site
    Pointe Claire, Quebec H9R 3J1, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Pfizer Investigational Site
    Ste Foy, Quebec G1V 3M7, Canada
  • Pfizer Investigational Site
    Guangzhou, Guangdong 510630, China
  • Pfizer Investigational Site
    Nanjing, Jiangsu 210008, China
  • Pfizer Investigational Site
    Chengdu, Sichuan 610041, China
  • Pfizer Investigational Site
    Beijing, 100020, China
  • Pfizer Investigational Site
    Beijing, 100044, China
  • Pfizer Investigational Site
    Beijing, 100073, China
  • Pfizer Investigational Site
    Beijing, 100853, China
  • Pfizer Investigational Site
    Shanghai, 200001, China
  • Pfizer Investigational Site
    Shanghai, 200040, China
  • Pfizer Investigational Site
    Tianjin, 300052, China
  • Pfizer Investigational Site
    Tianjin, 300192, China
  • Pfizer Investigational Site
    Medellin, Antioquia 0, Colombia
  • Pfizer Investigational Site
    Barranquilla, Atlantico 0, Colombia
  • Pfizer Investigational Site
    Barranquilla, Atlantico, Colombia
  • Pfizer Investigational Site
    Bogota, Cundinamarca 0, Colombia
  • Pfizer Investigational Site
    Floridablanca, Santander 0, Colombia
  • Pfizer Investigational Site
    Cartago, Costa Rica
  • Pfizer Investigational Site
    Heredia, Costa Rica
  • Pfizer Investigational Site
    San Jose, 3er piso., Costa Rica
  • Pfizer Investigational Site
    San Jose, Costa Rica
  • Pfizer Investigational Site
    Opatija, 51410, Croatia
  • Pfizer Investigational Site
    Zagreb, 10000, Croatia
  • Pfizer Investigational Site
    Plzen, Bory 30599, Czechia
  • Pfizer Investigational Site
    Ostrava, Trebovice 722 00, Czechia
  • Pfizer Investigational Site
    Ceske Budejovice, 370 01, Czechia
  • Pfizer Investigational Site
    Hradec Kralove, 50012, Czechia
  • Pfizer Investigational Site
    Prague 1, 118 00, Czechia
  • Pfizer Investigational Site
    Praha 2, 120 00, Czechia
  • Pfizer Investigational Site
    Praha 2, 128 50, Czechia
  • Pfizer Investigational Site
    Praha 4, 140 59, Czechia
  • Pfizer Investigational Site
    Praha 6, 16900, Czechia
  • Pfizer Investigational Site
    Cuenca, Azuay, Ecuador
  • Pfizer Investigational Site
    Guayaquil, Guayas, Ecuador
  • Pfizer Investigational Site
    Quito, Pichincha, Ecuador
  • Pfizer Investigational Site
    Tallinn, 11312, Estonia
  • Pfizer Investigational Site
    Tallinn, 13419, Estonia
  • Pfizer Investigational Site
    Tartu, 51007, Estonia
  • Pfizer Investigational Site
    Amiens, 80030, France
  • Pfizer Investigational Site
    Dijon, 21000, France
  • Pfizer Investigational Site
    Berlin, 12247, Germany
  • Pfizer Investigational Site
    Berlin, 13125, Germany
  • Pfizer Investigational Site
    Deggingen, 73326, Germany
  • Pfizer Investigational Site
    Dresden, 01129, Germany
  • Pfizer Investigational Site
    Hamburg, 22143, Germany
  • Pfizer Investigational Site
    Hamburg, 22415, Germany
  • Pfizer Investigational Site
    Hoyerswerda, 02977, Germany
  • Pfizer Investigational Site
    Kuenzing, 94550, Germany
  • Pfizer Investigational Site
    Muenchen, 80639, Germany
  • Pfizer Investigational Site
    Nuernberg, 90402, Germany
  • Pfizer Investigational Site
    Thessaloniki, 54 636, Greece
  • Pfizer Investigational Site
    Ciudad de Guatemala, Guatemala
  • Pfizer Investigational Site
    Guatemala 01010, Guatemala
  • Pfizer Investigational Site
    Lai Chi Kok, Hong Kong
  • Pfizer Investigational Site
    Shatin, Hong Kong
  • Pfizer Investigational Site
    Hyderabad, Andhra Pradesh 500 033, India
  • Pfizer Investigational Site
    Bangalore, Karnataka 560 034, India
  • Pfizer Investigational Site
    Bangalore, Karnataka 560 079, India
  • Pfizer Investigational Site
    Bangalore, Karnataka 560054, India
  • Pfizer Investigational Site
    Ludhiana, Punjab 141 001, India
  • Pfizer Investigational Site
    Seoul, 110-744, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 133-792, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 135-710, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 137-040, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 138-736, Korea, Republic of
  • Pfizer Investigational Site
    Riga, LV 1002, Latvia
  • Pfizer Investigational Site
    Riga, LV 1006, Latvia
  • Pfizer Investigational Site
    Riga, LV 1038, Latvia
  • Pfizer Investigational Site
    Alytus, LT-62114, Lithuania
  • Pfizer Investigational Site
    Kaunas, LT-47144, Lithuania
  • Pfizer Investigational Site
    Kaunas, LT-50425, Lithuania
  • Pfizer Investigational Site
    Klaipeda, LT-94231, Lithuania
  • Pfizer Investigational Site
    Vilnius, LT-07156, Lithuania
  • Pfizer Investigational Site
    Vlaardingen, ZH 3136 LA, Netherlands
  • Pfizer Investigational Site
    Alkmaar, 1815 JD, Netherlands
  • Pfizer Investigational Site
    Leidschendam, 2262 BA, Netherlands
  • Pfizer Investigational Site
    Ciudad de Panama, Panama
  • Pfizer Investigational Site
    Surco, Lima Lima 33, Peru
  • Pfizer Investigational Site
    Lima, 27, Peru
  • Pfizer Investigational Site
    Lima, L11, Peru

Showing the first 100 of 195 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kellner HL, Li C, Essex MN. Celecoxib and Diclofenac Plus Omeprazole are Similarly Effective in the Treatment of Arthritis in Patients at High GI Risk in the CONDOR Trial. Open Rheumatol J. 2013 Nov 13;7:96-100. doi: 10.2174/1874312901307010096. eCollection 2013. PubMed 24358067 ↗
  • Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010 Jul 17;376(9736):173-9. doi: 10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16. Erratum In: Lancet. 2011 Jul 16;378(9787):228. PubMed 20638563 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2005
First posted
Sep 1, 2005
Start
Oct 2005
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Jun 11, 2010
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00141102
Responsible party
Sponsor
First posted
Sep 1, 2005
Start date
Oct 2005
Primary completion
May 2009
Completion
May 2009
Results posted
Jun 11, 2010
Last update
Mar 3, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion